The theme of the moment is strikingly clear right now: Cannabis growth. With the full legalization of recreational “adult use” cannabis in Canada earlier today, the stage is set for the emergence of a number of new related plays that haven’t been found yet by the crowd.

One of the most interesting such opportunities is PreveCeutical Medical Inc. (CSE: PREV ; OTC: PRVCF).

The company is already emerging as a leadership in alternative medicine, helping to find solutions to the opioid crisis. However, now, in recent days, we have learned that the company may be nearing the acquisition of a major diversified firm with market-ready products targeting the North American cannabis market.

The stock is extremely interesting right now precisely because it may be about to become the Next Big Thing in the cannabis space, but the market hasn’t priced that in.

Symbol:  (CSE: PREV ; OTC: PRVCF)

Company:  PreveCeutical Medical Inc.

Quote:  http://finance.yahoo.com/q?s=PRVCF

Latest News: http://finance.yahoo.com/q/h?s=PRVCF+Headlines

Company Website:  https://www.preveceutical.com/

 Key Points:

  • PRVCF is conducting due diligence towards acquiring a diversified company with huge cannabis exposure and a number of market-ready products that could generate instant revenue growth.
  • PRVCF shares recently broke out higher from an accumulation base on rising volume. A strong technical signal.
  • PRVCF is coming off an RSI trough under 40, pointing to a massively oversold stock now heading back the other way.
  • PRVCF just recorded a MACD Bullish reversal, suggesting a bullish technical change in trend.
  • PRVCF also just established a key JV to develop products aimed at the legal cannabis market, which is expected to reach $146.4 billion by end of 2025, according to Grand View Research.

PreveCeutical Medical Inc. (CSE: PREV ; OTC: PRVCF) is a health sciences company that develops options for preventive and curative therapies utilizing organic and nature identical products.

As suggested above, it is one of very few stocks out there with significant cannabis growth potential that hasn’t been picked up and launched higher by momentum traders.

It has research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.

The company offers CELLB9 immune system booster, an oral solution containing polarized and potentiated essential minerals extracted from a peptide obtained from Caribbean blue scorpion venom. It also provides medicinal cannabis-based products.

The company has a research and option agreement with University of Queensland; and the UniQuest Pty Limited to develop non-addictive analgesics for the treatment of pain. It also has a strategic research and development supply agreement with Aurora Cannabis to produce medical cannabis.

Recent Catalysts

(CSE: PREV ; OTC: PRVCF) just announced the formation of a JV with Asterion Cannabis Incto develop “a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches, and other jointly evaluated products aimed at treating various ailments, such as chronic pain, inflammation, epilepsy and anxiety disorders.”

In a period when anything and everything associated with cannabis has been heading into orbit, this JV has to be viewed as extremely promising.

Mr. Stephen Van Deventer, PreveCeutical’s Chairman, CEO and President, stated, “This agreement between PreveCeutical and Asterion further supports our mission to improve global health and healthcare by utilizing innovative science and cutting-edge technology to enhance natural products. Our joint venture with Asterion comes at an important time, using Asterion’s high quality, low cost, genetically uniform strains of medicinal cannabis will allow PreveCeutical to supply the anticipated increasing demand for effective and personalised cannabis-based therapies.”

In addition, as noted above, (CSE: PREV ; OTC: PRVCF) also just announced that it has entered into a letter of intent with Penta 5with respect to a strategic acquisition whereby PreveCeutical would acquire the Penta 5 Group and its assets.

The big point here is this: Penta 5 includes over 120 market-ready products and a 150,000 square foot state-of-theart packaging facility, including market-ready products encompassing cannabis, beverage, industrial, and medical packaging industry segments.

As we said earlier, the cannabis space is absolutely exploding right now, and the crowd is only just starting to discover PreveCeutical.

Looking at the Chart

The chart for (CSE: PREV ; OTC: PRVCF) is another explosive reasonwhy we want to put this stock in front of you right now. The pattern suggests a very strong support level held between $0.02-0.03 through July and August that may represent a potential influx of “smart money” accumulation.

The stock then exploded off that bullish base, breaking above both its former downtrend line and the 50-day simple moving average on a jump in trading volume.

Shares of (CSE: PREV ; OTC: PRVCF) ran over 300% in September, and have done a nice healthy job of consolidating those gains over the past 10 days.

Which leaves us right now with a very interesting stock:New emerging bullish energy on the charts amid signs that the company is on the verge of establishing significant interest in the cannabis space at exactly the time when that space is swelling with investment capital.

About (CSE: PREV ; OTC: PRVCF)

PreveCeutical Medical Inc. is a health sciences company that develops options for preventive and curative therapies utilizing organic and nature identical products.

It has research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.

The company offers CELLB9 immune system booster, an oral solution containing polarized and potentiated essential minerals extracted from a peptide obtained from Caribbean blue scorpion venom. It also provides medicinal cannabis-based products. The company has a research and option agreement with University of Queensland; and the UniQuest Pty Limited to develop non-addictive analgesics for the treatment of pain. It also has a strategic research and development supply agreement with Aurora Cannabis to produce medical cannabis.

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. MarijuanaStox.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor. This Advertorial was paid for by a third party in an effort to enhance public awareness of PreveCeutical Medical Inc. and its securities. DF Media has  received five thousand dollars by World Wide Holdings on 10/16/2018 as a total production budget for this advertising effort. Neither MarijuanaStox.com or DF Media currently holds the securities of PreveCeutical Medical Inc. and does not currently intend to purchase such securities. This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at www.sec.gov readers can review all public filings by the Company at the SEC’s EDGAR page. MarijuanaStox.com is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Wynn & Encore Las Vegas Casino Has Banned MassRoots CEO From Gambling
13 June 2017
South Carolina Voters Vote in Favor of Legalizing Medicinal Marijuana
13 June 2018
New Zealanders Inch Closer to Being Able to Vote for Marijuana
23 May 2018